Lantern Pharma Establishes AI Center in India
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Lantern Pharma announced the establishment of an AI center of excellence and advanced agentic labs in Bengaluru, India. The initiative is designed to industrialize its AI-driven drug discovery capabilities at a global scale. The center will focus on data engineering, refining ML-ready disease models, and integrating with global biopharma customers. Lantern stated the expansion is expected to be cash flow neutral.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like LTRN with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on LTRN
Wall Street analysts forecast LTRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LTRN is 25.00 USD with a low forecast of 25.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.170
Low
25.00
Averages
25.00
High
25.00
Current: 3.170
Low
25.00
Averages
25.00
High
25.00
About LTRN
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
New to The Street Highlights Blockchain and Oncology Innovations in Episode #710
- Blockchain Infrastructure Acceleration: TokenFI's Chief Revenue Officer Pedro Vidal discussed strategies for accelerating institutional adoption of blockchain tokenization, aiming to build scalable, compliance-ready infrastructure for real asset issuance, which is expected to drive transformation in financial markets.
- New Oncology Treatment Platform: NeOnc Technologies' CEO Amir Heshmatpour introduced an intranasal drug delivery platform targeting aggressive brain cancers along with its clinical and regulatory roadmap, potentially providing new treatment options and improving survival rates for patients.
- AI-Driven Drug Discovery: Lantern Pharma's CEO Panna Sharma outlined their AI-driven approach to oncology drug discovery, enhancing research speed and capital efficiency, which is anticipated to increase clinical success rates and expedite new drug market entry.
- Infrastructure Investment Strategy: Mataterra Holdings' co-chairmen Monika Proffitt and Douglas Anderson provided strategic insights on global infrastructure development and real asset tokenization, emphasizing the importance of capital formation to meet future market demands.
Continue Reading
Lantern Pharma Announces Encouraging Phase 1a Results for LP-184 in Advanced Solid Tumors
Clinical Study Results: Lantern Pharma's Phase 1a dose-escalation study of LP-184 demonstrated promising disease control in patients with advanced solid tumors and DNA damage repair deficiencies, meeting all safety and tolerability endpoints.
Future Plans: The company intends to progress LP-184 into multiple Phase 1b/2 trials following the successful outcomes of the initial study.
Continue Reading